Johnson & Johnson (JNJ): FY24 Q4 earnings call, Jan 22, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jan 22, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
2 matches for “Ottava”; 2 quoted, at least 25 words apart.
…we progressed 18 clinical trial programs including the IDE approval of our OTTAVA robotic surgical system, which allows clinical trials to begin at US sites.…
…to the FDA for Impella ECP regulatory approval, continued progress on our OTTAVA robotic surgical system and advancements across our cardiovascular portfolio, including electrophysiology, heart…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-01-22:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-01-22:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP